Boston Scientific Enters U.S. Atrial Flutter Market With EPT-1000 XP
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific aims to carve out a leading share of the estimated $50-$60 mil. worldwide atrial flutter market opportunity with the EPT-1000 XP cardiac ablation system, the firm says
You may also be interested in...
Biosense Webster Touts Ablation Catheters’ Atrial Flutter Curative Properties
Successful ablation using Biosense Webster's NaviStar DS and Celsius DS catheters can cure and eliminate atrial flutter arrhythmia in cases where available pharmaceutical treatments are only palliative, according to the firm
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.